KRAS and lung carcinoma: Low-level gains and mutations co-occurred significantly more frequently than expected for KRAS (gain in 24% of mutated tumors versus 18% in non-mutated tumors, q = 0.02) in the TCGA dataset, as reported before in lung cancer [26], and KRAS (gain in 40% of mutated cel lines versus 23% in non-mutated cell lines, q = 1.0e−03) and BRAF (gain in 65% of mutated cell lines versus 40% in non-mutated cell lines, q = 5.0–06) in the CCLE dataset, while no mutually exclusive patterns were detected.